TAKEDA PHARMACEUTICALS PARTNERS WITH WESTWOOD & WILSHIRE TO FILL THE GLOBAL REGULATORY LEAD NOROVIRUS

Takeda Pharmaceuticals – among the top pharmaceutical companies in the world and one of the fastest growing with a U.S. Hub in Massachusetts that includes the operational center for Takeda’s Global Vaccines Business Unit - has hired Frederick de Brito as their new Global Regulatory Lead for the innovative Norovirus Vaccine program. Fredrick has joined from GSK Biologicals (formerly Novartis Vaccines) where he served as the Director of Global Regulatory Affairs and where he successfully managed the integration of legacy Novartis vaccines. Earlier in his career, he also worked at Biotest Pharmaceuticals, Shire, Amgen and Eli Lilly.

The search was successfully led by Tamir Halaban at Westwood & Wilshire of Westwood & Wilshire’s Life Sciences practice.

At Westwood & Wilshire, we recognize that people are an organization's top asset. We are passionate about delivering premier talent to the world’s most innovative companies. We are particularly focused on companies ranging from VC-backed start-ups to mid-sized commercial entities and our assignments range from C-Suite to mid-management. Our firm has offices in Los Angeles, Silicon Valley, and Seattle, serving clients on a local, national and global basis.